Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2024-04-16 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a future event: a webinar to present a strategic co-development and licensing agreement with AbbVie. It contains standard press release elements like contact information, forward-looking statements, and disclaimers about investment advice. This type of announcement, which communicates material corporate news via a press release format, most closely aligns with a general regulatory announcement or a specific event announcement. Since it is not a full report (10-K, IR), an earnings release (ER), or a specific transaction notice (like DIV or CAP), and it is announcing a presentation about a strategic deal, it fits best under the general Regulatory Filings (RNS) category, as it is a formal, non-standardized communication of material information to the market. It is not a Call Transcript (CT) as it is an announcement *about* a call, not the transcript itself. Given the content is a press release announcing a strategic partnership and an upcoming presentation, RNS is the most appropriate general classification.
2024-04-16 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing a strategic co-development and licensing agreement between Medincell and AbbVie. It details the financial terms (upfront payment and potential milestones) and the nature of the partnership. This falls under M&A Activity (TAR) as it relates to a significant corporate partnership and licensing deal.
2024-04-16 English
Informations privilégiées / Autres communiqués
M&A Activity Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a major strategic co-development and licensing agreement between Medincell and AbbVie regarding long-acting injectable treatments. It details financial terms (initial payment, potential milestones, royalties) and the scope of the collaboration. This type of announcement, which details significant business development, partnership, or material corporate events outside of routine financial reporting (like 10-K or ER), typically falls under a general regulatory announcement category. Since it is not a specific financial report (10-K, IR, ER), a management discussion (MDA), or a capital change (CAP/SHA), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements not covered by more specific codes.
2024-04-16 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a "PRESS RELEASE" announcing that Unitaid has awarded Medincell an extension grant of up to $6 million to fund clinical phase 1 activities for an investigational malaria treatment (mdc-STM). This is a specific corporate announcement regarding funding/grants related to development activities, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal regulatory filing detailing insider trades (DIRS) or shareholder votes (DVA). It details a financing/grant event related to capital/development, which aligns best with the 'Capital/Financing Update' category, although it is primarily a partnership/grant announcement. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for a major grant announcement impacting future development funding, as it relates directly to securing resources for operations/development. It is not an Earnings Release (ER) or a general Regulatory Filing (RNS) because it is highly specific.
2024-04-08 English
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that MedinCell will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024. It details the presentation topics (commercial and advanced-development portfolio) and provides context on recent commercial milestones (UZEDY launch) and pipeline progress. This type of announcement, focusing on participation in an external investor/industry conference, is best classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about an upcoming presentation. Since the text is an announcement about presenting at a conference, it falls under the general category of investor relations communication. Given the options, 'Investor Presentation (IP)' is the closest fit for content related to presenting portfolio and strategy to investors, even though this specific document is the *announcement* of the presentation, not the presentation slides themselves. However, if we strictly follow the 'MENU VS MEAL' rule, a short announcement about an upcoming event might lean towards RPA or RNS. But the content is substantial and focuses on strategic updates (UZEDY revenue guidance, Phase 3 candidates), making it more substantive than a simple 'Report Publication Announcement' (RPA). In the context of investor relations documents, conference presentations are often grouped with Investor Presentations (IP). I will classify it as IP as it directly relates to presenting investment-relevant information at a major industry event.
2024-03-27 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated March 27, 2024, announcing that MedinCell executives will participate in the 23rd annual Needham Virtual Healthcare conference on April 11, 2024. It details the presentation topics (product portfolio, clinical pipeline updates like UZEDY commercialization and Phase 3 candidates) and provides registration links. This type of announcement, which publicizes executive participation in an external industry event to discuss company performance and pipeline, is best classified as an Investor Presentation (IP) or, more accurately in this context where it's an announcement *about* presenting, it often falls under general Investor Relations communication. However, since the core content is an update on business progress, commercialization (UZEDY), and clinical pipeline (Phase 3 candidates), it strongly aligns with the content typically found in an Investor Presentation (IP). It is not a full Earnings Release (ER) as it focuses on conference participation and pipeline updates rather than comprehensive period results, nor is it a Call Transcript (CT). Given the focus on presenting pipeline and commercial progress to investors at a conference, 'Investor Presentation' (IP) is the most fitting category for the *subject matter* being presented, even though this specific document is the *announcement* of that presentation. If a specific 'Conference Participation Announcement' code existed, it would be used, but among the given options, IP captures the essence of the information being shared with investors.
2024-03-27 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.